BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

BCRX 11.10 -0.20 (-1.77%)
price chart
BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable
The drug development company said Thursday it's consulting the WHO at a meeting in Geneva this week. BioCryst, which is developing its BCX4430 Ebola drug candidate -- the drug with $24.4 million from the National Institutes of Health -- said August 29 ...
Related articles »  
Biotechs With Massive Upside [BioCryst Pharmaceuticals, Inc., Alexion ...
Two American missionaries and a Spanish priest received an experimental cocktail of three humanized (from nonhuman species; modified to enhance similarity to human) antibodies called ZMapp, which is being developed by Mapp Pharmaceutical Inc.
Biotech Roundup: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Novavax ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) [Trend Analysis] declared trial results associated to RAPIVA, a neuraminidase inhibitor for the cure of influenza.
Related articles »  
Stocks Alert: Tesla Motors Inc (NASDAQ:TSLA), BioCryst Pharmaceuticals, Inc ...
Shares of Tesla Motors Inc (NASDAQ:TSLA) are climbing after research firm Stifel upgraded the stock to Buy from Hold in a note to investors today, citing optimism about demand for the company's electric automobiles. Tesla Motors Inc (NASDAQ:TSLA) ...
Related articles »  
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results ...
As per the clinical trial results achieved by the BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), peramivir is probably the first NAI (neuraminidase inhibitor) which is quite effective and safe for patients as a single-dose therapy.
BioCryst Pharma (BCRX) Reports RAPIVAB Trial Results at ICAAC Meeting  StreetInsider.com (subscription)
BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza ...  CNNMoney
Related articles »  
Trader's Buzzers - BioCryst Pharmaceuticals, Inc. (BCRX), Uranium Energy Corp ...
Birmingham, West Midlands - (TechSonian) - 25 August 2014 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase 1 clinical ...
BioCryst Pharmaceuticals Receives Consensus Rating of "Buy" from Analysts ...
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals (NASDAQ:BCRX) has earned a consensus rating of �Buy� from the twelve brokerages that are covering the company, Stock Ratings Network reports. Two research analysts have rated the stock with a ...
WHO Offers Update on Ebola Outbreak for Aug. 17 - 18 (TKMR) (BCRX) (NLNK)  StreetInsider.com (subscription)
Related articles »  
Stocks Alert-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), NovaGold ...
Manhattan, NY- September 2, 2014 - (Techsonian) �BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX)declared that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract modification for an additional $2.4 million to BioCryst ...
Insider Selling: BioCryst Pharmaceuticals CFO Sells 10000 Shares of Stock ...  Watch List News (press release)
Insider Selling: Thomas R. Staab II Sells 10000 Shares of BioCryst ...  sleekmoney
Related articles »  
Active Runners � BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Rentech, Inc ...
Manhattan, NY- Sept 04, 2014 - (Techsonian) �BioCryst Pharmaceuticals, Inc. (BCRX) recently updated that its participation in a consultation on potential Ebola therapies and vaccines hosted by the World Health Organization (WHO).
Intraday Movers: BioCryst Pharmaceuticals, Inc. (BCRX), Dejour Energy Inc ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) unveiled trial results related to RAPIVAB(TM) (peramivir injection), a neuraminidase inhibitor (NAI) for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy ...